Teriflunomide
Teriflunomide is an active ingredient of the class «immunosuppressive drug».
Chemical compound
Boxed warning (US label)
HEPATOTOXICITY and EMBRYOFETAL TOXICITY Hepatotoxicity Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with AUBAGIO in the postmarketing setting.
What it is used for
- Multiple sclerosis
- Relapsing-remitting multiple sclerosis
AUBAGIO ® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).
How it works
- Dihydroorotate dehydrogenase inhibitor
Class: immunosuppressive drug
Common side effects
The following clinically significant adverse reactions are described elsewhere in the prescribing information: Hepatotoxicity Bone Marrow Effects/Immunosuppression Potential/Infections Hypersensitivity Reactions Serious Skin Reactions Drug Reaction with Eosinophilia and Systemic Symptoms Cutaneous or Mucocutaneous…
Who should not take it
Severe hepatic impairment Pregnancy Hypersensitivity Current leflunomide treatment AUBAGIO is contraindicated in/with: Patients with severe hepatic impairment.
Pregnancy and breastfeeding
AUBAGIO is contraindicated for use in pregnant women and females of reproductive potential not using effective contraception because of the potential for fetal harm based on animal data.
Interactions
- Atorvastatin
- Benzylpenicillin
- Cimetidine
- Ciprofloxacin
- Duloxetine
- Erlotinib
- Furosemide
- Ketoprofen
- Leflunomide
- Levonorgestrel
- Methotrexate
- Paclitaxel
- Pioglitazone
- Pravastatin
- Repaglinide
- Rifampicin
- Rosuvastatin
- Simvastatin
- Tizanidine
- Warfarin
- Zidovudine
Brand names
United States
Aubagio
European Union
Aubagio · Teriflunomide Accord · Teriflunomide Viatris (previously Teriflunomide Mylan)
Canada
Apo-Teriflunomide · Auro-Teriflunomide · Jamp Teriflunomide · M-Teriflunomide · Nat-Teriflunomide · Pms-Teriflunomide · Sandoz Teriflunomide · Teva-Teriflunomide
Other trade names
Teriflunomide mylan
Approval status
- US Food and Drug Administration
- prescription · since 2012
- European Medicines Agency
- authorised · since 2013
- Health Canada
- prescription · marketed
- First approval anywhere
- 2012
Codes
- ATC
- L04AA31, L04AK02
- RxNorm CUI
- 1310520
- ChEMBL
- CHEMBL973
- PubChem CID
- 54684141
- UNII
- 1C058IKG3B
- Wikidata
- Q3077133
Frequently asked questions
What is Teriflunomide used for?
Teriflunomide is used for: Multiple sclerosis and Relapsing-remitting multiple sclerosis.
What kind of medicine is Teriflunomide?
Teriflunomide is an active ingredient of the class «immunosuppressive drug».
What are the brand names of Teriflunomide?
Brand names of Teriflunomide include Aubagio, Teriflunomide Accord, Teriflunomide Viatris (previously Teriflunomide Mylan), Apo-Teriflunomide, Auro-Teriflunomide, Jamp Teriflunomide, M-Teriflunomide, and Nat-Teriflunomide.
Medicines in the same class
- Sirolimus
- Adalimumab
- Everolimus
- Leflunomide
- Fingolimod
- Cladribine
- Apremilast
- Tofacitinib
- Mycophenolate mofetil
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)